Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application - Cancer Treatment Reviews
Is dehydroepiandrosterone a hormone? in: Journal of Endocrinology Volume 187 Issue 2 (2005)
Safety and Efficacy | Zoladex® (goserelin implant)
Frontiers | Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs | Oncology
Will GnRH antagonists improve prostate cancer treatment?: Trends in Endocrinology & Metabolism
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
Endocrinology of Prostate Cancer - ppt download
Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer | SpringerLink
Advances in the Management of Metastatic Breast Cancer; Hormonal Therapy and Targeted Agents (Slides with Transcript)
Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer - Van Poppel - 2020 - International Journal of Urology - Wiley Online Library
Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy | NEJM
Zoladex' (goserelin) adjuvant to radical
Zoladex' (goserelin) - ppt video online download
Bone Metastases from Prostate Cancer: Hormonal Therapy | Oncohema Key
Oncology
Gonadotropin-releasing-hormone-receptor antagonists - The Lancet
Slowing the PSA | prost8blog
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations | Prostate Cancer and Prostatic Diseases
Frequently Asked Questions About Zoladex® (Goserelin) - CancerConnect
Golexin 3.6mg - AMW GmbH - Arzneimittelwerk Warngau - english Version
Zoladex 3-month (AstraZeneca), Drug Reference Encyclopedia
Goserelin - Wikipedia
Zoladex ca mammae
